Goldman Sachs
VNDA icon

Goldman Sachs’s Vanda Pharmaceuticals VNDA Stock Holding History

Goldman Sachs’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,100
Closed -$62K – 6430
2017
Q4 		$62K Sell
4,100
-69,300
-94% -$1.03M ﹤0.01% 5889
2017
Q3 		$1.31M Buy
73,400
+19,700
+37% +$330K ﹤0.01% 4347
2017
Q2 		$875K Buy
53,700
+52,500
+4,375% +$757K ﹤0.01% 4586
2017
Q1 		$17K Sell
1,200
-12,000
-91% -$171K ﹤0.01% 6548
2016
Q4 		$211K Sell
13,200
-4,400
-25% -$70.7K ﹤0.01% 5737
2016
Q3 		$293K Sell
17,600
-85,300
-83% -$1.15M ﹤0.01% 5499
2016
Q2 		$1.15M Buy
102,900
+9,600
+10% +$93K ﹤0.01% 4072
2016
Q1 		$780K Sell
93,300
-4,000
-4% -$32.8K ﹤0.01% 4312
2015
Q4 		$906K Buy
97,300
+86,500
+801% +$863K ﹤0.01% 4398
2015
Q3 		$122K Sell
10,800
-97,600
-90% -$1.19M ﹤0.01% 6361
2015
Q2 		$1.38M Sell
108,400
-72,300
-40% -$780K ﹤0.01% 4225
2015
Q1 		$1.68M Buy
180,700
+97,700
+118% +$1.1M ﹤0.01% 3959
2014
Q4 		$1.19M Sell
83,000
-5,100
-6% -$60.3K ﹤0.01% 4383
2014
Q3 		$914K Buy
88,100
+52,400
+147% +$687K ﹤0.01% 4700
2014
Q2 		$578K Sell
35,700
-1,000,500
-97% -$13.3M ﹤0.01% 5181
2014
Q1 		$16.8M Buy
1,036,200
+574,600
+124% +$8.17M 0.01% 1918
2013
Q4 		$5.73M Sell
461,600
-405,300
-47% -$4.07M ﹤0.01% 2935
2013
Q3 		$9.49M Buy
866,900
+658,300
+316% +$7.03M ﹤0.01% 2308
2013
Q2 		$1.69M Buy
+208,600
New +$1.4M ﹤0.01% 3884

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's VNDA Position: Q1 2026 in Review

Goldman Sachs increased its Vanda Pharmaceuticals (VNDA) stake by 105% in Q1 2026, buying an estimated $3.32M and bringing the position to 838,233 shares worth $5.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3559.

Goldman Sachs first reported a position in VNDA in Q2 2013 and has held it in 52 quarters since. The position peaked at $39.1M in Q1 2015. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Goldman Sachs held 838,233 shares of Vanda Pharmaceuticals worth $5.79M as of Q1 2026.
  • Goldman Sachs bought 429,891 Vanda Pharmaceuticals shares in Q1 2026, an estimated $3.32M.
  • Vanda Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3559 holding.
  • Goldman Sachs first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Vanda Pharmaceuticals position peaked at $39.1M in Q1 2015.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.